265 results on '"Grenier, Julien"'
Search Results
2. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
3. Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML
4. Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program
5. Évaluation des besoins pour la mise en place d’une Unité de Thérapie Orale
6. RETRACTED ARTICLE: Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer
7. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
8. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
9. Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.
10. Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.
11. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
12. Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France
13. Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia
14. Withdrawal notice to « Patients sous Palbociclib et hormonothérapie pour un cancer du sein métastatique : peut-on prédire la survenue d’une hématotoxicité précoce et sévère ? » [Bull Cancer 108 (2021) 544–552 https://doi.org/10.1016/j.bulcan.2021.01.007]
15. Flow Cytometry Analysis of Mouse Hematopoietic Stem and Multipotent Progenitor Cells
16. Circadian Expression of Migratory Factors Establishes Lineage-Specific Signatures that Guide the Homing of Leukocyte Subsets to Tissues
17. Involvement of β-Catenin and Unusual Behavior of CBP and p300 in Glucocorticosteroid Signaling in Schwann Cells
18. L26-3 Mimer la niche érythroïde avec un modèle 3D multicellulaire
19. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
20. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
21. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
22. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
23. Effect of physical exercise on brain and lipid metabolism in mouse models of multiple sclerosis
24. Liver X Receptors differentially modulate central myelin gene mRNA levels in a region-, age- and isoform-specific manner
25. GPR56/ADGRG1 is associated with response to antidepressant treatment
26. Antidepressive effects of targeting ELK-1 signal transduction
27. Dépistage du cancer du sein : en route vers le futur
28. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
29. Liver X receptors alpha and beta promote myelination and remyelination in the cerebellum
30. Abstract P4-07-54: Health related quality of life of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2 negative metastatic breast cancer: impact of clinical factors
31. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
32. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
33. Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer
34. Évaluation des besoins pour la mise en place d’une Unité de Thérapie Orale
35. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
36. Differential regulation of Wnt/beta-catenin signaling by Liver X Receptors in Schwann cells and oligodendrocytes
37. Lithium enhances remyelination of peripheral nerves
38. A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer (305)
39. Wnt and lithium: a common destiny in the therapy of nervous system pathologies?
40. RNA-Seq is not required to determine stable reference genes for qPCR normalization
41. Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)
42. WITHDRAWN: Patients sous palbociclib et hormonothérapie pour un cancer du sein métastatique : peut-on prédire la survenue d’une hématotoxicité précoce et sévère ?
43. Immune-Related Genetic Overlap Between Regional Gray Matter Reductions and Psychiatric Symptoms in Adolescents, and Gene-Set Validation in a Translational Model
44. Author Reply to Peer Reviews of RNA-Seq is not required to determine stable reference genes for qPCR normalization
45. Adhesion Molecules Involved in Stem Cell Niche Retention During Normal Haematopoiesis and in Acute Myeloid Leukaemia
46. Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA -mutant advanced breast cancer: Data from the French early access program
47. Corrigendum to “Differential regulation of Wnt/beta-catenin signaling by Liver X Receptors in Schwann cells and oligodendrocytes” [Biochem. Pharmacol. 86 (2013) 106–114]
48. RNA-Seq is not required to determine stable reference genes for qPCR normalization
49. Ineffective Erythropoiesis Negatively Impacts the Erythroblastic Island in Sickle Cell Disease
50. New Insights into Cellular Defects during Haematopoiesis of Sickle Cell Disease Using the Townes Mouse Model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.